New Hampshire Medicaid Fee-for-Service Program
Elevidys (delandistorgene moxeparvovec-rokl) Criteria

Approval Date: January 22, 2024

Medications

Brand Names	Generic Name	Indication
Elevidys	delandistrogene moxeparvovec-rokl	indicated for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene

Criteria for Approval

1. Patient is age 4 through 5 years of age; **AND**
2. Patient has been diagnosed with Duchenne muscular dystrophy (DMD); **AND**
3. Patient has a confirmed mutation of the DMD gene between exons 18 to 58; **AND**
4. Patient must have a baseline anti-AArh74 total binding antibody titer of < 1:400 as measured by ELISA; **AND**
5. Patient is ambulatory as confirmed by the North Star Ambulatory Assessment (NSAA) scale (score of ≥ 1); **AND**
6. Patient is not on concomitant therapy with DMD-directed antisense oligonucleotides (e.g. golodirsen, casimersen, viltolarsen, eteplirsen); **AND**
7. Patient has not received a DMD-directed antisense oligonucleotides within the past 7 days; **AND**
8. Patient does not have an active infection, including clinically important localized infections; **AND**
9. Patient has been on a stable dose of a corticosteroid, unless contraindicated or intolerance, prior to the start of therapy and will be used concomitantly with a corticosteroid regimen pre- and post-infusion (refer to the package insert for recommended corticosteroid dosing during therapy); **AND**
10. Patient's troponin-1 levels will be monitored at baseline and subsequently as clinically indicated; **AND**
11. Patient will have liver function assessed prior to and following therapy for at least 3 months and as indicated.

Limitation

A single dose per lifetime. 1 kit based on patient weight.

Criteria for Denial

Above criteria are not met.

References

Available upon request.

Revision History

Reviewed by	Reason for Review	Date Approved
DUR Board	New	12/08/2023
Commissioner Designee	Approval	01/22/2024